Zanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell Lymphoma

For patients who met the inclusion criteria, treatment regimens were administered: Rituximab 375 mg/m², intravenously, once weekly for 4 weeks. Zanubrutinib 160 mg, orally, twice daily for 4 weeks. Combined drugs: prednisone 100 mg/m²/d, orally, d1-5; Ruxolitinib 15mg bid orally; With/without emapalumab as appropriate.

Trial Details

NCT ID
NCT07270835
Phase
PHASE4
Sponsor
The First Affiliated Hospital of Soochow University
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • Rituximab
  • Zanubrutinib
Locations (sample)
  • Suzhou, Jiangsu, China|31.30408,120.59538

Key Eligibility Criteria

  • According to the diagnostic criteria of HLH-04, the patients meet the diagnostic criteria of HLH;
  • HLH patients with definite or highly suspected evidence of B-cell lymphoma; Or HLH patients whose bone marrow flow cytometry show an increased prop…
  • Age of 14-80 years old, both sexes;
  • Predicted survival beyond 1 month;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →